inflammasome Inhibitors
3 drugsAbout inflammasome
The inflammasome is a multi-protein complex in the innate immune system. It activates inflammatory responses by processing pro-inflammatory cytokines like IL-1β and IL-18, triggering pyroptosis.
The inflammasome is a therapeutic target due to its role in inflammation. Currently, there is no genetic evidence directly linking the inflammasome to specific diseases.
Three FDA-approved drugs target the inflammasome: COLCRYS, GLOPERBA, and MITIGARE. All three drugs are small molecules, addressing various therapeutic areas.
Strategic Insights
ℹ️ How we calculate- Validated target with strong trial activity and 80% attractiveness score.
- White space opportunity in Ischemic Stroke with only 2 trials.
Top Drugs
The competitive landscape includes three companies with approved drugs: AR HOLDING CO INC, SCILEX PHARMS, and Hikma.
The limited number of players suggests a relatively unconcentrated market with potential entry opportunities.
Drug Modality Landscape
Modalities
Routes of Administration
inflammasome is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
Clinical Trials 212 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 35 | 30 | 1 | 4 | 97% |
| Phase 2 | 66 | 38 | 12 | 16 | 76% |
| Phase 3 | 61 | 25 | 6 | 29 | 81% |
| Phase 4 | 50 | 27 | 5 | 17 | 84% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2009 - 2019)
The first drug targeting the inflammasome was approved in 2009 (COLCRYS), with the most recent approval in 2019 (GLOPERBA).
The approval timeline indicates a slow but steady interest in targeting this pathway, suggesting room for innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 158 clinical trials targeting inflammasome.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities